Congestive Heart Failure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for congestive heart failure. 13 active patents protecting 1 drugs from 1+ originators. First major cliff: 2032. Daily refresh.

1
Approved drugs
13
Active US patents
38/100
Avg vulnerability
—
Annual revenue covered

Originators in Congestive Heart Failure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Azurity 13 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating congestive heart failure. Each bar = one year. Y-axis scaled to peak year (9 patents).

4
32
9
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vasotec
ENALAPRIL MALEATE
 Azurity 13 38 — 2032-11-06

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8778366 Vasotec method of use 55 2032-11-06
9968553 Vasotec method of use 50 2032-11-06
9808442 Vasotec method of use 50 2036-03-25
10154987 Vasotec method of use 50 2036-03-25
11173141 Vasotec formulation 38 2036-03-25
8568747 Vasotec formulation 35 2032-11-06
9855214 Vasotec formulation 30 2032-11-06
10772868 Vasotec formulation 30 2036-03-25
10039745 Vasotec formulation 30 2036-03-25
10786482 Vasotec formulation 30 2036-03-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11040023 Vasotec formulation 30 2036-03-25
10039745 Vasotec formulation 30 2036-03-25
10786482 Vasotec formulation 30 2036-03-25
11141405 Vasotec formulation 30 2036-03-25
9669008 Vasotec formulation 30 2036-03-25
10772868 Vasotec formulation 30 2036-03-25
9855214 Vasotec formulation 30 2032-11-06
8568747 Vasotec formulation 35 2032-11-06
11173141 Vasotec formulation 38 2036-03-25
9808442 Vasotec method of use 50 2036-03-25

Related